| Nov 19 |
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
|
| Nov 19 |
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
|
| Oct 16 |
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
|
| Oct 16 |
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
|
| Oct 15 |
Alzamend Neuro regains compliance with Nasdaq
|
| Oct 15 |
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
|
| Oct 10 |
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
|
| Aug 26 |
Alzamend Neuro Issues Letter to Stockholders
|
| Aug 20 |
Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
| Aug 19 |
Top Midday Gainers
|
